Monascus purpureus and application of selenium-rich monascus purpureus prepared from monascus purpureus
Through the fermentation of the 1322 strain of Rhodobacteria purple with high yield of lovastatin and low yield of citronomycin, Rhodobacteria selenium-rich Aspergillus selenite, the problem of hyperlipidemia was solved, significantly reduced the weight and fat proportion of mice, and regulated the Serum lipid levels inhibit inflammatory factors and liver damage.
Patent Information
- Application Number
- CN202411152016.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-21
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-08-21
AI Technical Summary
The prior art failed to effectively combine Aspergillus violet and selenium elements, and failed to solve the problem of hyperlipidemia.
The strain of Aspergillus 1322 of Rhodobacteria purple, which is highly produced lovastatin and low yielding tangerinecin, was prepared by fermenting with sodium selenite, which significantly reduced hyperlipidemia.
It significantly reduced the weight and fat proportion of mice, regulated the serum triglycerides, total cholesterol and low-density lipoprotein levels, inhibited the production and release of inflammatory factors, and relieved liver damage and oxidative stress.
Smart Images

Figure CN119020170A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of microorganisms, and in particular relates to purple monascus and application of selenium-enriched monascus prepared therefrom. Background Art
[0002] Hyperlipidemia is a common metabolic disease, characterized by blood lipid levels such as triglycerides (TG), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) exceeding the normal range. Dyslipidemia is often closely related to the onset of cardiovascular diseases such as atherosclerosis and coronary heart disease. In addition, people with high blood lipid levels also have problems such as sleep disorders and depression. The lipid-lowering drugs currently on the market mainly include statins, fibrates, niacin, etc. As oral drugs for lowering blood lipids, statins have been most widely recognized for their excellent effects. As the core organ of human metabolism, the liver can achieve precise regulation of lipid metabolism by participating in complex processes such as the synthesis and decomposition of cholesterol and triglycerides, thereby maintaining the balance of lipid levels in the body.
[0003] Monascus purpureus is a filamentous fungus that can produce a variety of physiologically active metabolites such as lovastatin and monascus pigment, and has a wide range of applications in the food and pharmaceutical fields. Lovastatin is highly similar in structure to hydroxymethylglutaryl-CoA reductase, the rate-limiting enzyme in the cholesterol synthesis process, and can react competitively with it, inhibiting the synthesis of cholesterol, thereby achieving the effect of lowering blood lipids.
[0004] Selenium (Se), as an essential trace element for mammals, cannot be synthesized by the body itself and must be supplemented through external intake. Selenium deficiency can cause Kashin-Beck disease and Keshan disease. In addition, selenium plays a potential role in anti-aging, anti-viral infection, cardiovascular disease prevention and cancer prevention. Selenium exists in nature in the form of inorganic selenium and organic selenium. Inorganic selenium is severely restricted because it is difficult to be absorbed by the human body, has low bioavailability and high toxicity. Organic selenium from organisms has low toxicity and high bioavailability, and is an important source of selenium for humans from food.
[0005] How to combine the effects of purple Monascus and selenium to obtain a strain with combined effects has not been solved in the prior art. Summary of the invention
[0006] In order to solve the above technical problems, the present invention proposes an application of a purple Monascus and a selenium-enriched Monascus prepared therefrom, wherein the purple Monascus 1322 with high lovastatin production, low citrinin production and strong selenium resistance is used as a strain, sodium selenite is used as a selenium source, and the selenium-enriched Monascus is obtained by fermentation. The obtained selenium-enriched Monascus has the effect of significantly reducing hyperlipidemia.
[0007] To achieve the above-mentioned purpose, the present invention provides a purple Monascus 1322, which is taxonomically named as purple Monascus 1322 Monascus purpureus 1322. The purple Monascus 1322 was deposited in the China Center for Type Culture Collection on August 9, 2024, and the preservation address is Wuhan University, No. 299, Bayi Road, Wuchang District, Wuhan City, Hubei Province, and the preservation number is: CCTCCNO: M 20241767.
[0008] The present invention also provides a method for preparing selenium-enriched Monascus by using the purple Monascus 1322, comprising the following steps: inoculating a spore suspension of the purple Monascus 1322 into a culture medium containing sodium selenite, and culturing on a shaking table for 8 to 10 days to obtain selenium-enriched Monascus.
[0009] Preferably, the inoculation amount of the spore suspension of Monascus purpurogenum 1322 is 8% by volume, and the concentration of sodium selenite in the culture medium is 2-6 μg / mL.
[0010] Preferably, the effective bacterial count in the spore suspension of Monascus purpurogenus 1322 is 10 6 ~10 7 Pieces / mL.
[0011] Preferably, the rotation speed of the shaking incubator is 180 rpm, and the temperature of the shaking incubator is 28°C.
[0012] The invention also provides selenium-enriched Monascus prepared by the method.
[0013] The present invention also provides the use of the selenium-enriched Monascus in preparing a product with the effect of lowering blood lipids.
[0014] The present invention also provides a medicine with blood lipid lowering effect, wherein the medicine uses the selenium-enriched Monascus as an effective active ingredient.
[0015] Preferably, the drug further comprises a pharmaceutically acceptable excipient.
[0016] Compared with the prior art, the present invention has the following advantages and technical effects:
[0017] The present invention uses purple Monascus 1322 with high lovastatin production, low citrinin production and strong selenium resistance as strains, sodium selenite as a selenium source, and obtains selenium-enriched Monascus by fermentation. The obtained selenium-enriched Monascus has the effect of significantly reducing hyperlipidemia, which is specifically manifested in reducing the weight and fat percentage of mice, regulating the levels of triglycerides, total cholesterol and low-density lipoprotein in serum, inhibiting the production and release of inflammatory factors LPS and TNF-α in serum, and alleviating liver damage and oxidative stress. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0019] Figure 1 is the phylogenetic tree;
[0020] Figure 2 The figure is the screening result of purple Monascus strains with high lovastatin production and low citrinin production, wherein A is the lovastatin content produced by purple Monascus, and B is the citrinin content produced by purple Monascus;
[0021] Figure 3 The following are statistical graphs of the weight changes and fat percentage of mice in each group, where A is a graph of mouse morphology changes, B is a graph of mouse weight changes, C is a graph of mouse weight gain, and D is a graph of mouse fat percentage;
[0022] Figure 4 The statistical graphs of changes in blood lipid levels of mice in each group, among which A is the statistical graph of TC levels, B is the statistical graph of TG levels, C is the statistical graph of LDL-C levels, and D is the statistical graph of HDL-C levels;
[0023] Figure 5 The statistical graphs of inflammatory factors levels in each group of mice, among which A is the statistical graph of LPS level, and B is the statistical graph of TNF-α level;
[0024] Figure 6 The liver morphology of mice in each group, A is the surface morphology of the liver of mice in each group, and B is the liver morphology of mice in each group after HE staining;
[0025] Figure 7 The liver damage evaluation diagrams of mice in each group, where A is the statistical diagram of ALT levels and B is the statistical diagram of AST levels;
[0026] Figure 8 Statistical graphs of oxidative stress levels of mice in each group, wherein A is the statistical graph of CAT levels, B is the statistical graph of T-SOD levels, and C is the statistical graph of MDA levels. DETAILED DESCRIPTION
[0027] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0028] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.
[0029] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.
[0030] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to the skilled artisan. The present invention description and examples are exemplary only.
[0031] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.
[0032] The purple Monascus 1322 described in the present invention is taxonomically named as purple Monascus 1322 Monascus purpureus 1322. The purple Monascus 1322 was deposited in the China Center for Type Culture Collection on August 9, 2024, and the preservation address is Wuhan University, No. 299, Bayi Road, Wuchang District, Wuhan City, Hubei Province, and the preservation number is: CCTCC NO: M 20241767.
[0033] Sources of materials used in the present invention: purple monascus strain 8.542, purple monascus strain 1314, purple monascus strain 1322, purple monascus strain 1324, purple monascus strain 1422, purple monascus strain 2322, purple monascus strain 3421, purple monascus strain 4421, purple monascus strain 4424, purple monascus strain 4425, purple monascus strain 6421, purple monascus strain 7321, purple monascus strain 7413, purple monascus strain 40268 and purple monascus strain 41601 are all preserved in the Healthy Food Manufacturing and Safety Control Engineering Laboratory of Northwest Agriculture and Forestry University; potato dextrose agar medium (PDA) was purchased from Beijing Land Bridge Technology Co., Ltd.
[0034] The culture medium used in the present invention is as follows: Seed culture medium: 30 g glucose, 20 g peptone, 50 mL glycerol, 1 g KH 2 PO 4 , 2gNaNO 3 、1g MgSO 4 7H 2 O, 2g ZnSO 4 7H 2 O, add water to make up to 1000mL;
[0035] Fermentation medium: 25 g glucose, 20 g peptone, 50 mL glycerol, 1 g KH 2 PO 4 , 2gNaNO 3 、1g MgSO 4 7H 2 O, 2g ZnSO 4 7H 2 O. 25g rice flour, add water to make up to 1000mL.
[0036] Data processing and statistical analysis of the present invention: All experiments were repeated at least 3 times, and the values were expressed as mean ± standard deviation (SD). GraphPad Prism 9.0 software was used for drawing. SPSS26 software and Duncan's test were used for significance analysis. Different lowercase letters indicate significant differences, p < 0.01.
[0037] Example 1
[0038] Strain screening and isolation: Weigh 5g of red yeast rice, grind it into powder with a mortar, and place it in 100mL of sterile saline, and shake it in a shaker for 30 minutes. After mixing, dilute the suspension in a gradient concentration (dilution factor of 10 to 10 5 ), 100 μL of sample dilutions of different concentrations were respectively transferred and evenly spread on PDA medium, and cultured at 28°C for one week. Single colonies were transferred to PDA medium by the spot grafting method, and single colonies consistent with the appearance of Monascus were obtained through repeated separation and purification.
[0039] Strain identification: The DNA of Monascus was extracted using a kit method. The extracted total DNA of Monascus was used as a template and the fungal ITS universal primers ITS1 and ITS4 were used for polymerase chain reaction amplification. The PCR amplification system used a 20 μL system: ddH 2O6μL, 1μL each of forward and reverse primers, 10μL of PCR Supermix, and 2μL of DNA template. The amplification program is: 94℃ pre-denaturation for 5min; 94℃ denaturation for 1min, 55℃ annealing for 1min, 72℃ extension for 1min, 36 cycles; 72℃ extension for 10min. After PCR amplification, 6.0μL of amplified product was taken for agarose gel electrophoresis, 1.5g of agarose was added to 90mL TAE buffer solution (1.5%), microwave heating for 1min and shaken well, 8μL of Gelred dye solution was added and mixed, the solidified gel was placed in 1×TAE electrophoresis solution, and the electrophoresis program was set for electrophoresis: time 20min, voltage 120V, current 300mA, power 250W. The samples were then sent to Shanghai Sangon Biotechnology Co., Ltd. for sequencing, and the sequencing results were subjected to BLAST multiple sequence alignment analysis in the NCBI database, and the phylogenetic tree was further constructed by the neighbor-joining method in the MEGA software (such as Figure 1 Combined with the morphological observation results, the strain was identified as Monascus purpureus 1322 and named as Monascus purpureus 1322.
[0040] Example 2
[0041] 1. Screening of purple Monascus strains with high lovastatin production and low citrinin production
[0042] Activation of strains: Inoculate the purple Monascus strain on the slant culture medium (PDA) and culture at 28°C for 6 days. To ensure the activity and purity of the strain, repeat the above activation steps twice before proceeding with subsequent operations.
[0043] Preparation of spore suspension: Sterile physiological saline was injected into the activated strain to fully elute the spores. The concentration of spore suspension was adjusted to 10 using a hemocytometer under a microscope. 6 ~10 7 Spores / mL range.
[0044] Preparation of seed solution: Inoculate 100 mL of seed culture medium (100 mL of liquid in a 250 mL conical flask) with a spore suspension at a volume fraction of 8%, and culture in a shaker at 28° C. and 180 rpm for 48 h.
[0045] Preparation of fermentation broth: Inoculate 8% of the seed liquid into 100 mL of fermentation medium (250 mL of liquid volume 100 mL), and culture in a shaker at 28°C and 180 rpm for 10 days.
[0046] Determination of lovastatin: After ultrasonication of a mixture of 1 mL of fermentation broth and 3 mL of anhydrous ethanol, the supernatant obtained by centrifugation is filtered with a 0.22 μm syringe filter and then analyzed on the machine. Liquid phase conditions: chromatographic column Chromegabond WR C18 (250×4.6 mm, 5 μm); mobile phase acetonitrile: 0.1% phosphoric acid water = 65:35 (v / v); flow rate: 1.0 mL / min; column temperature: 30°C; injection volume: 10 μL; detector is a UV detector with a wavelength of 238 nm.
[0047] Determination of citrinin: After 1 mL of fermentation broth and 1 mL of methanol mixture are water-bathed, the supernatant obtained by centrifugation is filtered with a 0.22 μm syringe filter and then analyzed by a machine. Liquid phase conditions: chromatographic column Chromegabond WR C18 (250×4.6 mm, 5 μm); mobile phase is acetonitrile: 0.01% phosphoric acid water = 65:35 (v / v); flow rate: 1.0 mL / min; column temperature: 30°C; injection volume: 10 μL; detector is a fluorescence detector, λex = 331 nm, λem = 500 nm.
[0048] Lovastatin standard and citrinin standard were purchased from Shanghai Yuanye Biotechnology Co., Ltd.; chromatographic phosphoric acid was purchased from Komiou Chemical Reagent Co., Ltd.; chromatographic acetonitrile and methanol were purchased from TEDIA Reagent Co., Ltd., USA.
[0049] The results of lovastatin and citrinin production by purple Monascus strains are shown in the following table. Figure 2 As shown, Figure 2 As shown in A, purple Monascus strains 8.542, 1322, 1422, 2322, 4421, 4424, 4425 and 40268 produced lovastatin at a level higher than 20 μg / mL; Figure 2 As shown in B, the citrinin content of purple Monascus strains 8.542, 1322, 1324, 1422, 2322, 3421, 4424 and 6421 was less than 20 μg / mL. Therefore, purple Monascus strains 8.542, 1322, 1422, 2322 and 4424 were selected for the subsequent evaluation of selenium resistance.
[0050] 2. Screening of selenium-resistant purple Monascus strains
[0051] The selenium tolerance of the purple Monascus strains 8.542, 1322, 1422, 2322 and 4424 was evaluated. The Monascus spore suspension in step "1" was inoculated into a PDA medium containing 10 μg / mL sodium selenite. The culture was carried out at 28°C for 15 days, and the tolerance of the purple Monascus strain to selenium was evaluated based on the colony diameter of the strain. The larger the colony diameter, the stronger the selenium resistance of the purple Monascus. The results are shown in Table 1.
[0052] Table 1 Evaluation of selenium resistance of purple Monascus strains
[0053]
[0054] Note: “–” indicates that no colony growth was detected; “+” indicates that the colony diameter is greater than 5 mm; “++” indicates that the colony diameter is greater than 30 mm; “+++” indicates that the colony diameter is greater than 50 mm.
[0055] As shown in Table 1, the selenium resistance of the five purple Monascus strains is presented. The results show that purple Monascus strains 1322 and 1422 can be observed in selenium-containing medium on the 3rd day, purple Monascus strains 2322 and 4424 can be observed on the 7th day, and purple Monascus strain 8.542 only starts to grow on the 10th day. The colony diameter of purple Monascus strain 1322 began to be larger than that of purple Monascus strain 1422, purple Monascus strain 2322 and purple Monascus strain 4424 on the 10th day, and this situation continued until the 15th day, indicating that purple Monascus strain 1322 has a stronger selenium resistance and was selected as the subsequent selenium-enriched strain for lipid-lowering evaluation.
[0056] 3. Study on the lipid-lowering effect of selenium-enriched Monascus
[0057] The purple Monascus strain 1322, which was screened out for high lovastatin production, low citrinin production and strong selenium resistance, was used as the test strain to evaluate its lipid-lowering effect.
[0058] Preparation of selenium-enriched Monascus fermentation broth: Inoculate the seed culture medium into the liquid fermentation medium (100 mL of liquid in a 250 mL conical flask) at an inoculum volume fraction of 8%, add sodium selenite solution thereto to make the final concentrations reach 2 and 6 μg / mL, respectively. Cultivate in a shaker at 28°C at 180 rpm for 10 days to obtain selenium-enriched Monascus fermentation broth.
[0059] Reagents and materials: Four-week-old male C57BL / 6J mice were purchased from Chongqing Tengxin Biotechnology Co., Ltd. Xi'an Branch; basal feed and high-fat feed were purchased from Jiangsu Collaborative Pharmaceutical Bioengineering Co., Ltd.; simvastatin tablets were purchased from Shandong Xinqi Pharmaceutical Co., Ltd. as a positive drug.
[0060] Modeling: After one week of adaptive culture, all mice were randomly divided into 6 groups, with 12 mice in each group, namely: normal diet group (ND), high-fat diet group (HFD), simvastatin group (HFD-Y), purple Monascus group (HFD-M), low-dose selenium-enriched Monascus group (HFD-LSM) and high-dose selenium-enriched Monascus group (HFD-HSM). In the experiment, except for the ND group, which was fed with a basic feed (3790 kcal / kg), the other groups were fed with a high-fat feed (5128 kcal / kg). From the 9th week, the ND group and the HFD group began to receive normal saline by gavage, the HFD-Y group received simvastatin with a concentration of 0.345 mg / mL by gavage, the HFD-M group received purple Monascus suspension by gavage, and the HFD-LSM and HFD-HSM groups received selenium-enriched Monascus suspension cultured with 2 and 6 μg / mL sodium selenite, respectively. The daily gavage volume of each group was 0.2 mL. All mice had free access to food and water throughout the study, and their body weights were measured weekly.
[0061] Mouse sacrifice: After several weeks of dietary intervention, the mice were sacrificed. The mice were fasted for 12 hours before sacrifice, anesthetized by intraperitoneal injection of 4% chloral hydrate, fresh blood was obtained by eyeball bleeding, serum was separated by centrifugation at 4°C, and finally the serum was transferred to a clean centrifuge tube for subsequent analysis. After the sacrifice operation was completed, the liver was quickly removed for photographing and the whole body fat was weighed. Part of the liver was fixed in 4% paraformaldehyde for HE staining analysis, and the rest of the liver and fat were quickly frozen with liquid nitrogen and placed in a -80°C ultra-low temperature refrigerator for subsequent research.
[0062] Fat percentage calculation: Fat percentage (%) = total body fat weight / mouse body weight*100%
[0063] Determination of blood lipid levels: TC, TG, LDL-C and HDL-C kits (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) were used to measure TC, TG, LDL-C and HDL-C in mouse serum. The specific operations were carried out according to the instructions of each kit.
[0064] Analysis of serum inflammatory factors: LPS and TNF-α kits (Shanghai Kexing Trading Co., Ltd., Shanghai, China) were used to measure LPS and TNF-α indicators in mouse serum. For relevant operations, please refer to the kit instructions.
[0065] Pathological observation of animal liver: fresh livers were photographed to record their original state, and a small amount of liver tissue was cut and fixed with 4% paraformaldehyde, embedded in paraffin, sectioned, and stained with hematoxylin and eosin, and then pathological morphology was observed using an inverted microscope.
[0066] Evaluation of liver injury: AST and ALT kits (Yacoin Biotechnology Co., Ltd., Wuhan, China) were used to measure ALT and AST in mouse serum. For relevant operations, please refer to the instructions of the kit.
[0067] Animal liver oxidative stress analysis: CAT, MDA and T-SOD kits were used to measure CAT, MDA and T-SOD indicators in mouse liver. For relevant operations, please refer to the kit instructions. CAT and MDA kits were purchased from Yacoin Biotechnology Co., Ltd., and T-SOD kit was purchased from Nanjing Jiancheng Bioengineering Institute.
[0068] The results of the study are as follows:
[0069] 1. Results of mouse weight changes and fat percentage Figure 3 As shown, specifically Figure 3 Middle A, Figure 3 Middle B, Figure 3 Middle C and Figure 3 As shown in D, the weight of mice in the normal diet group was significantly lower than that in the high-fat diet group during the modeling stage, indicating that the modeling was successful. After dietary intervention, the frequency of weight gain of mice in the HFD-Y, HFD-M, HFD-LSM and HFD-HSM groups decreased, and their weights were between the HFD group and the ND group. The fat percentage of the HFD group was significantly higher than that of the ND group, and drug and dietary intervention significantly reduced the fat percentage. Surface selenium-enriched Monascus and purple Monascus 1322 play a good role in lipid reduction.
[0070] 2. The results of blood lipid levels in each group of mice are as follows Figure 4 The specific results are shown in Figure 4 Middle A, Figure 4 Middle B, Figure 4 Middle C and Figure 4 As shown in D, dietary intervention reduced TC, TG and LDL-C levels, and increased HDL-C levels, so that the four blood lipid levels of the HFD-Y, HFD-M, HFD-LSM and HFD-HSM groups were between the ND group and the HFD group, indicating that both Monascus purpurogenum 1322 and selenium-enriched Monascus had a certain positive effect on regulating blood lipid levels.
[0071] 3. The statistical results of the inflammatory factor content in the serum of each group of mice are as follows Figure 5 The specific results are shown in Figure 5 Middle A and Figure 5As shown in B, in the ND group, the levels of LPS and TNF-α in serum were 321.90 and 899.59 ng / L, respectively, and in the HFD group, the levels of the two inflammatory factors increased to 444.03 and 1246.73 ng / L, respectively, indicating that a high-fat diet is prone to cause inflammatory reactions. Dietary intervention reduced the levels of the two inflammatory factors and gradually approached the ND group, indicating that both purple Monascus 1322 and selenium-enriched Monascus can better inhibit the production and release of inflammatory factors.
[0072] 4. The liver morphology of mice in each group is as follows Figure 6 As shown, specifically Figure 6 In A, the surface of the liver of mice in the ND group was usually smooth and uniformly reddish brown. The liver was moderately sized, soft and elastic. The liver had a clear outline without obvious swelling or protrusions. In the liver of mice in the HFD group, the color of the liver was slightly dull and the whole liver became swollen, indicating that some pathological changes may have occurred. Dietary intervention alleviated the swelling of the organs. The liver was further stained with HE, as shown in Figure 2. Figure 6 As shown in B, the liver cells of mice in the ND group were observed to be normal in morphology, regularly arranged, with clearly visible nuclei and abundant organelles in the cytoplasm. The liver cells of mice in the HFD group showed fat accumulation, which was manifested by the enlargement and increase in the number of fat cells, a significant increase in intracellular lipid droplets, and the infiltration of inflammatory cells, which was manifested by the increase in macrophages in the liver sinusoids. After dietary intervention, liver cells showed signs of reduction or repair of some pathological phenomena, mainly manifested by reduced fat accumulation and weakened cavitation.
[0073] 5. ALT and AST are enzymes present in liver cells, which are released into the blood when liver cells are damaged or destroyed. Therefore, the liver damage can be evaluated to a certain extent by measuring the ALT and AST levels in serum. Figure 7 Middle A and Figure 7 As shown in B, the results showed that compared with the ND group, the ALT and AST levels in the serum of mice in the HFD group were significantly increased. The increase in ALT and AST levels indicated that the high-fat diet caused liver damage in mice, resulting in inflammation, necrosis or fibrosis of liver cells, which was consistent with the HE staining results. Both purple Monascus 1322 and selenium-enriched Monascus can reduce the levels of ALT and AST, and the effect of selenium-enriched Monascus is better, which indicates that selenium-enriched Monascus has a better protective effect on the liver of hyperlipidemic mice.
[0074] Under the condition of hyperlipidemia, lipid metabolism disorder will increase the level of oxidative stress, leading to an increased risk of liver oxidative damage. Therefore, the common antioxidant enzyme activities of CAT and T-SOD and the lipid peroxidation product MDA were measured respectively. The results are as follows: Figure 8 Middle A, Figure 8 Medium B and Figure 8 As shown in C, in the ND group, the contents of CAT and T-SOD were 67.41 nmol / min / mL and 92.36 U / mL, respectively, and in the HFD group, their contents dropped to 59.65 nmol / min / mL and 77.39 U / mL, respectively. After dietary intervention, the contents of CAT and T-SOD in the liver showed an upward trend, and the effects of the HFD-HSM and HFD-LSM groups were better than those of the HFD-M group, especially the changes in the T-SOD index were more significant, indicating that both purple Monascus 1322 and selenium-enriched Monascus could alleviate the changes in CAT and T-SOD contents caused by a high-fat diet, and the effect of selenium-enriched Monascus was more obvious. The MDA content of the HFD group was 1.52 times that of the ND group. Dietary intervention could significantly reduce the MDA content in the liver, and the effect of selenium-enriched Monascus was not only better than that of the non-selenium-enriched purple Monascus 1322 bacterial suspension, but also dose-dependent. It can be seen that the introduction of selenium can make the obtained selenium-enriched Monascus exert a better antioxidant effect.
[0075] In summary, the present invention illustrates through the above embodiments that the present invention has indeed prepared selenium-enriched Monascus with the function of lowering blood lipids.
[0076] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.
Claims
1. A purple Monascus 1322, characterized in that: The taxonomic name is Monascus purpureus 1322. The Monascus purpureus 1322 was deposited in the China Center for Type Culture Collection on August 9, 2024. The preservation address is Wuhan University, No. 299, Bayi Road, Wuchang District, Wuhan City, Hubei Province, and the preservation number is: CCTCCNO: M 20241767.
2. A method for preparing selenium-enriched Monascus using the purple Monascus 1322 described in claim 1, characterized in that: The following steps are involved: The spore suspension of the purple Monascus 1322 is inoculated into a culture medium containing sodium selenite, and cultured on a shaking table for 8 to 10 days to obtain selenium-enriched Monascus.
3. The method for preparing selenium-enriched Monascus according to claim 2, characterized in that: The inoculation amount of the spore suspension of Monascus purpurogenus 1322 is 8% by volume, and the concentration of sodium selenite in the culture medium is 2-6 μg / mL.
4. The method for preparing selenium-enriched Monascus according to claim 2, characterized in that: The rotation speed of the shaking incubator is 180 rpm, and the temperature of the shaking incubator is 28°C.
5. The selenium-enriched Monascus prepared by the method according to any one of claims 2 to 4.
6. Use of the selenium-enriched Monascus as claimed in claim 5 in preparing a product having the effect of lowering blood lipids.
7. A drug having the effect of lowering blood lipids, characterized in that: The medicine uses the selenium-enriched Monascus as claimed in claim 5 as an effective active ingredient.
8. The drug according to claim 7, characterized in that: The drug also includes pharmaceutically acceptable excipients.
Citation Information
Patent Citations
Monascus ruber for high generation of lovastatin and gamma-aminobutyric acid and low generation of pigment, use thereof, and functional Monascus sp. prepared through using Monascus ruber
CN103224890A
Monascus purpureus strain
CN106399121A
Monasucspurpureus and application thereof
CN108034591A
Red monascus and application to preparation of fat-reducing medicines
CN108342327A
Purple monascus, method and application thereof for producing lovastatin through co-fermentation
CN110373332A
